Follow The Filings

RARE Ultragenyx Pharmaceutical In

Health Care, filed as ULTRAGENYX PHARMACEUTICAL IN (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 3 Owners
  • Max 5.0%
  • $35M
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed Ultragenyx Pharmaceutical In.

Who owns this now

Largest portfolio weights among holders, up to 5.0% (Michael Krensavage, Krensavage Asset Management). Not free-float ownership.

  1. Michael Krensavage 5.0%
  2. Palo Alto Investors 2.8%
  3. Nathan Fischel Reduce 0.30%

Who owns RARE

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 2.8% Hold 596,495 $20M History
Michael Krensavage, Krensavage Asset Management 5.0% Hold 390,879 $13M History
Nathan Fischel, Dafna Capital Management 0.30% Reduce −22.9% 47,100 $1.6M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RARE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RARE insider trades
  • None no insider bought on the open market
  • $2.5M sold by 8 insiders outside a trading plan
  • $1.3M sold by 4 insiders under 10b5-1 plans
  1. Howard Horn CFO
    Sale
    $108K 7,066 shares at $15.27 7.3% of stake
    Traded Oct 15 Filed Oct 19
    ↗
  2. Theodore Alan Huizenga SVP, Chief Accounting Officer
    Planned sale
    $17K 1,283 shares at $13.57 1.9% of stake
    Traded Sep 15 Filed Sep 15
    ↗
  3. Theodore Alan Huizenga SVP, Chief Accounting Officer
    Sale
    $2,252 161 shares at $13.99 0.2% of stake
    Traded Sep 3 Filed Sep 8
    ↗
  4. Karah Herdman Parschauer EVP and Chief Legal Officer
    Planned sale
    $47K 1,900 shares at $24.92 2% of stake
    Traded Aug 3 Filed Aug 4
    ↗
  5. Howard Horn CFO
    Planned sale
    $117K 4,696 shares at $24.92 4.6% of stake
    Traded Aug 3 Filed Aug 4
    ↗
  6. Howard Horn CFO
    Planned sale
    $156K 4,698 shares at $33.13 4.4% of stake
    Traded Jul 1 Filed Jul 6
    ↗
  7. Corazon (Corsee) D. Sanders Director
    Sale
    $50K 2,000 shares at $25.05 8.7% of stake
    Traded Jun 15 Filed Jun 15
    ↗
  8. Karah Herdman Parschauer EVP and Chief Legal Officer
    Planned sale
    $47K 1,899 shares at $24.62 2% of stake
    Traded Jun 15 Filed Jun 15
    ↗
  9. Howard Horn CFO
    Planned sale
    $111K 4,653 shares at $23.77 4.2% of stake
    Traded Jun 1 Filed Jun 1
    ↗
  10. Shehnaaz Suliman Director
    Planned sale
    $144K 5,740 shares at $25.12 17% of stake
    Traded May 18 Filed May 18
    ↗
  11. Eric Crombez EVP and Chief Medical Officer
    Sale
    $8,586 344 shares at $24.96 0.3% of stake
    Traded May 5 Filed May 6
    ↗
  12. Howard Horn CFO
    Planned sale
    $117K 4,683 shares at $24.90 4.1% of stake
    Traded May 1 Filed May 4
    ↗
  13. Howard Horn CFO
    Planned sale
    $98K 4,683 shares at $20.97 5.5% of stake
    Traded Apr 1 Filed Apr 2
    ↗
  14. Karah Herdman Parschauer EVP and Chief Legal Officer
    Sale
    $208K 9,526 shares at $21.87 13% of stake
    Traded Mar 6–10 Filed Mar 10
    ↗
  15. John Richard Pinion See Remarks
    Sale
    $229K 10,029 shares at $22.80 8.4% of stake
    Traded Mar 2 Filed Mar 3
    ↗

Also filed in the last 12 months, not counted as buying or selling: 22 stock grants and 2 share withholdings for taxes.

Congress

1 member of Congress traded RARE in the last three years: 5 buys and 0 sales. 1 member listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Sep 29 filed Oct 12
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Feb 18 filed Mar 9
  4. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Aug 8, 2025 filed Sep 12, 2025
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jul 15, 2025 filed Aug 14, 2025

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 8.01 Filing Doc
8-K 1.01 Filing Doc
8-K 1.01 Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $434.25M $560.23M $673M
Net income -$606.64M -$569.18M -$575M
Net margin * -139.7% -101.6% -85.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $732.18M $817.12M $951M
Total non-current assets * $758.83M $686.33M $581M
Total assets $1.49B $1.5B $1.53B
Total current liabilities $280.44M $344.15M $384M
Total non-current liabilities * $0.935B $0.897B $1.22B
Total equity $275.41M $255.3M -$80M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$474.81M -$414.19M -$466M
Cash from investing $168M -$17.77M $236M
Cash from financing $388.14M $399.24M $478M
Net change in cash $81.8M -$35.24M $252M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.